isoniazid has been researched along with Alcohol Drinking in 23 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
Excerpt | Relevance | Reference |
---|---|---|
"Isoniazid (INH) preventive therapy is recommended to prevent tuberculosis (TB) disease for persons with HIV (PWH), except for those with regular and heavy alcohol consumption, due to hepatotoxicity concerns." | 8.31 | Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. ( Adong, J; Cheng, DM; Emenyonu, NI; Fatch, R; Hahn, JA; Jacobson, KR; Linas, BP; Muyindike, WR; Ngabirano, C; Terrault, NA; Tumwegamire, A, 2023) |
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
"To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study." | 7.79 | Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013) |
"Isoniazid (INH) preventive therapy is recommended to prevent tuberculosis (TB) disease for persons with HIV (PWH), except for those with regular and heavy alcohol consumption, due to hepatotoxicity concerns." | 4.31 | Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. ( Adong, J; Cheng, DM; Emenyonu, NI; Fatch, R; Hahn, JA; Jacobson, KR; Linas, BP; Muyindike, WR; Ngabirano, C; Terrault, NA; Tumwegamire, A, 2023) |
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
"To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study." | 3.79 | Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013) |
"Few studies have examined predictors of latent tuberculosis infection (LTBI) treatment completion in inner city populations in the United States." | 1.36 | Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. ( Bethel, J; Colson, PW; El-Sadr, W; Franks, J; Hirsch-Moverman, Y, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (43.48) | 18.7374 |
1990's | 3 (13.04) | 18.2507 |
2000's | 2 (8.70) | 29.6817 |
2010's | 5 (21.74) | 24.3611 |
2020's | 3 (13.04) | 2.80 |
Authors | Studies |
---|---|
Takiguchi, Y | 1 |
Nagayoshi, M | 1 |
Matsuura, Y | 1 |
Yokota, S | 1 |
Kajiwara, Y | 1 |
Akiba, Y | 1 |
Muyindike, WR | 2 |
Fatch, R | 2 |
Cheng, DM | 2 |
Emenyonu, NI | 2 |
Forman, L | 1 |
Ngabirano, C | 2 |
Adong, J | 2 |
Linas, B | 1 |
Jacobson, KR | 2 |
Hahn, JA | 2 |
Tumwegamire, A | 1 |
Terrault, NA | 1 |
Linas, BP | 1 |
Mukherjee, TI | 1 |
Hirsch-Moverman, Y | 3 |
Saito, S | 1 |
Gadisa, T | 1 |
Melaku, Z | 1 |
Howard, AA | 1 |
Park, S | 1 |
Jo, KW | 1 |
Lee, SD | 1 |
Kim, WS | 1 |
Shim, TS | 1 |
Pettit, AC | 1 |
Bethel, J | 2 |
Colson, PW | 2 |
Sterling, TR | 1 |
Yamada, S | 1 |
Tang, M | 1 |
Richardson, K | 1 |
Halaschek-Wiener, J | 1 |
Chan, M | 1 |
Cook, VJ | 1 |
Fitzgerald, JM | 1 |
Elwood, RK | 1 |
Brooks-Wilson, A | 1 |
Marra, F | 1 |
Tedla, Z | 1 |
Nyirenda, S | 1 |
Peeler, C | 1 |
Agizew, T | 1 |
Sibanda, T | 1 |
Motsamai, O | 1 |
Vernon, A | 1 |
Wells, CD | 1 |
Samandari, T | 1 |
Franks, J | 1 |
El-Sadr, W | 1 |
SCHUTH, W | 1 |
Wilcke, JT | 2 |
Døssing, M | 2 |
Angelo, HR | 1 |
Askgaard, D | 1 |
Rønn, A | 1 |
Christensen, HR | 1 |
Gupta, RC | 1 |
Nair, CR | 1 |
Jindal, SK | 1 |
Malik, SK | 1 |
Sbarbaro, JA | 1 |
Dickinson, DS | 1 |
Bailey, WC | 1 |
Hirschowitz, BI | 1 |
Soong, SJ | 1 |
Eidus, L | 1 |
Hodgkin, MM | 1 |
Rideout, M | 1 |
Menzies, R | 1 |
Askgaard, DS | 1 |
Nybo, B | 1 |
Clemmesen, J | 1 |
Hjalgrim-Jensen, S | 1 |
Kopanoff, DE | 1 |
Snider, DE | 1 |
Caras, GJ | 1 |
Ksiaźek, A | 1 |
Wojtczak, A | 1 |
Atuk, NO | 1 |
Hart, AD | 1 |
Hunt, EH | 1 |
Siegers, CP | 1 |
Mel'nik, VP | 1 |
Campbell, AH | 1 |
Guilfoyle, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana[NCT00164281] | Phase 4 | 2,000 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
Intervention | percent (Number) |
---|---|
INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
Intervention | Participants (Count of Participants) |
---|---|
INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
Intervention | Participants (Count of Participants) |
---|---|
Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
Intervention | Participants (Count of Participants) |
---|---|
Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
Intervention | pmol/mg (Median) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
Intervention | percentage of participants (Number) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
Intervention | days (Median) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
At 3 months72558043 | At 6 months72558043 | |||||||||||
Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
INH and Vitamin B6 | 160 | |||||||||||
INH and Vitamin B6 | 79 | |||||||||||
INH and Vitamin B6 | 38 | |||||||||||
INH and Vitamin B6 | 2 | |||||||||||
INH and Vitamin B6 | 124 | |||||||||||
INH and Vitamin B6 | 90 | |||||||||||
INH and Vitamin B6 | 41 | |||||||||||
INH and Vitamin B6 | 4 | |||||||||||
INH and Vitamin B6 | 0 | |||||||||||
INH and Vitamin B6 | 1 |
1 review available for isoniazid and Alcohol Drinking
Article | Year |
---|---|
Tuberculosis.
Topics: Alcohol Drinking; Carrier State; Chemical and Drug Induced Liver Injury; Ethambutol; Humans; Isoniaz | 1980 |
2 trials available for isoniazid and Alcohol Drinking
Article | Year |
---|---|
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Unchanged acetylation of isoniazid by alcohol intake.
Topics: Acetylation; Adult; Alcohol Drinking; Alcoholic Beverages; Antitubercular Agents; Area Under Curve; | 2004 |
20 other studies available for isoniazid and Alcohol Drinking
Article | Year |
---|---|
Thoracic empyema caused by Alloscardovia omnicolens and Bifidobacteriumdentium.
Topics: Actinobacteria; Alcohol Drinking; Empyema, Pleural; Humans; Isoniazid; Male; Middle Aged | 2022 |
Unhealthy Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in Persons With HIV in Southwestern Uganda.
Topics: Alcohol Drinking; Alcoholism; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male | 2022 |
Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
Topics: Alcohol Drinking; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Prospective Studies; Tub | 2023 |
Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia.
Topics: Adult; Alcohol Drinking; Alcoholism; Antitubercular Agents; Catha; Cross-Sectional Studies; Ethiopia | 2019 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
Topics: Adult; Alcohol Drinking; Antitubercular Agents; Canada; Female; Humans; Isoniazid; Latent Tuberculos | 2013 |
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
Topics: Acetylation; Adult; Aged; Alcohol Drinking; Antitubercular Agents; Arylamine N-Acetyltransferase; Br | 2009 |
Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience.
Topics: Adult; Alcohol Drinking; Antitubercular Agents; Emigrants and Immigrants; Female; Health Knowledge, | 2010 |
[SUICIDE ATTEMPT WITH NEOTEBEN AND SIMULTANEOUS ALCOHOL CONSUMPTION].
Topics: Alcohol Drinking; Alcoholic Intoxication; Humans; Isoniazid; Poisoning; Suicide; Suicide, Attempted; | 1964 |
Incidence of isoniazid acetylation phenotypes in North Indians.
Topics: Acetylation; Adult; Aging; Alcohol Drinking; Female; Humans; India; Isoniazid; Kinetics; Male; Middl | 1984 |
Risk factors for isoniazid (NIH)-induced liver dysfunction.
Topics: Acetylation; Age Factors; Alcohol Drinking; Chemical and Drug Induced Liver Injury; Female; Humans; | 1981 |
Factors affecting compliance with preventive treatment for tuberculosis at Mistassini Lake, Quebec, Canada.
Topics: Adult; Alcohol Drinking; Culture; Female; Health Knowledge, Attitudes, Practice; Humans; Indians, No | 1994 |
Liver injury during antituberculosis treatment: an 11-year study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antitubercular Agents; Aspartate Aminotransferases; Bilir | 1996 |
Is isonicotinic acid hydrazide (INH) carcinogenic to man? A 24-year follow-up of 3371 tuberculosis cases.
Topics: Alcohol Drinking; Carcinogens; Denmark; Female; Follow-Up Studies; Humans; Isoniazid; Lung Neoplasms | 1979 |
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Alkaline Phosphatase; Aspartate Aminotransferases; Bilir | 1978 |
[Acute renal failure with anuria of 30 days' duration after drinking ethyl alcohol during treatment with isoniazid].
Topics: Acute Kidney Injury; Alcohol Drinking; Anuria; Drug Interactions; Ethanol; Humans; Isoniazid; Male; | 1978 |
Close monitoring is essential during isoniazid prophylaxis.
Topics: Adult; Aged; Alcohol Drinking; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liv | 1977 |
[Alcohol intolerance in isoniazid therapy].
Topics: Alcohol Drinking; Automobile Driving; Drug Interactions; Ethanol; Expert Testimony; Germany, West; H | 1977 |
[Adverse effect of etiotropic agents in patients with tuberculosis].
Topics: Alcohol Drinking; Drug Hypersensitivity; Ethionamide; Humans; Isoniazid; Rifampin; Tuberculosis, Pul | 1991 |
Pulmonary tuberculosis, isoniazid and cancer.
Topics: Adult; Aged; Alcohol Drinking; Gastrointestinal Neoplasms; Humans; Isoniazid; Lung Neoplasms; Male; | 1970 |